MétaCan
Menu
Back to cohort
Record W2791721691 · doi:10.1093/jcag/gwy009.196

A196 AN EXTRA BENEFIT TO USING STATINS: A CLINICAL OBSERVATIONAL STUDY ON NAFLD PATIENTS (PILOT STUDY)

2018· article· en· W2791721691 on OpenAlex
Jianhui Zhou, Sanja Gauthier

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
aboutThe title or abstract carries a Canadian signal from the geographic lexicon.

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2018
Typearticle
Languageen
FieldHealth Professions
TopicDiverse Scientific Research Studies
Canadian institutionsHealth Sciences NorthThunder Bay Regional Health Sciences CentreUniversity of Ottawa
Fundersnot available
KeywordsObservational studyMedicinePhysical therapyInternal medicineIntensive care medicine

Abstract

fetched live from OpenAlex

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide – with an estimated 25% of Canadians affected. NAFLD has the potential to progress to nonalcoholic steatohepatitis (NASH), cirrhosis and fibrosis of the liver, and ultimately, liver failure. Globally, cirrhosis affects 1.6% people. NAFLD is often asymptomatic and found in people with metabolic syndrome. Both conditions can progress to an adverse event which relies on antidyslipidemic agents for treatment. The first-line of treatment for patients with dyslipidemia are statins. Recently, the use of statins has been suggested to be safe in NAFLD patients, but there is a lack in certainty of its effectivity in treating liver disease. To determine if statins are effective for NAFLD treatment. An observational study was conducted at the NorthGate Clinic, by searching for patients undergoing statin treatment with NAFLD suppression. A FibroScore was obtained for the patients to establish the severity of liver damage and NAFLD. Patients were then retested to obtain a post-stain use FibroScore. Alanine transaminase (ALT) and aspartate transaminase (AST) levels, another measure of liver condition, were also assessed with the continued usage of statins. After determining the cases with NAFLD, these cases were then included based on their improvement post-statin usage. A total of 27 patients from the NorthGate Clinic met the inclusion criteria. These NAFLD patients were on statins to treat some form of dyslipidemia, and found an additional benefit of the drug – suppression of the symptoms of and treatment of NAFLD. However, only 21 patients had pre- and post-FibroScore data. Overall, patients found a decrease in FibroScore, ALT and AST levels with the continued usage of statins. Evidence from the observational study indicated that the use of statins was associated with the suppression of NAFLD symptoms and a lower FibroScore, and ALT and AST levels. In general, this study suggests that the usage of statins was beneficial and safe in a particular sub-segment of the Canadian population with NAFLD. Therefore, suggesting that NAFLD patients are a population of interest. Limitations of the observational study included insufficient statistical power, uncontrolled selection bias and confounding factors. Moreover, since the data was obtained retrospectively, some data was missing. Thus, this study cannot assert that usage of statins induced an improvement to the liver (lower AST and ALT levels, and FibroScore). Currently, available studies indicate that the benefits of statins outweigh the adverse effects of these drugs in NAFLD patients. Additional research needs to be provided on the long-term side effects associated with the use of statins in this population. Future studies should focus on providing more evidence to support the effect of statins in NAFLD patients. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.004
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.660
Threshold uncertainty score0.997

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0070.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.379
GPT teacher head0.501
Teacher spread0.122 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it